[HTML][HTML] Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

I Attili, A Passaro, P Pisapia, U Malapelle… - Current Oncology, 2022 - mdpi.com
Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …

[HTML][HTML] Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma

R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

[HTML][HTML] Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and …

L Li, S Huang, L Qin, N Yan, S Shen, X Li - Frontiers in Pharmacology, 2023 - frontiersin.org
Background: The deletion of exon 19 and the Leu858Arg mutation of exon 21 are the most
frequently observed mutations in the epidermal growth factor receptor (EGFR) gene, and …

Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study

Y Qin, Y Long, Y Tang, Y Tian, J Li, P Duan… - Cancer …, 2023 - Wiley Online Library
Differently from epidermal growth factor receptor (EGFR) 19Del and L858R mutations, the
panoramic description of uncommon EGFR mutations is far from mature. Our understanding …

Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer-A Systematic Review

M Borgeaud, K Parikh, GL Banna, F Kim… - Journal of Thoracic …, 2024 - Elsevier
Introduction Uncommon EGFR mutations represent a rare subgroup of non-small cell lung
cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in …

[图书][B] EGFR-Directed Therapy in Lung Cancer

SY Kim, DB Costa, D Shibahara, S Kobayashi… - 2023 - cambridge.org
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a
clinically important driver alteration affecting approximately one-third of lung cancer patients …